89bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Posted: March 25, 2022 at 2:21 am

– Reported positive topline results from cohort 7 in the Phase 1b/2a trial including data from new analyses demonstrating the promising therapeutic utility of pegozafermin for the treatment of NASH –

Original post:
89bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Related Posts